Travere therapeutics provides corporate update and 2024 outlook

Received 459 new patient start forms for filspari ® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of filspari totaled $15 million for the fourth quarter

TVTX Ratings Summary

TVTX Quant Ranking